PT  - JOURNAL ARTICLE
AU  - Mina Ebrahimi
AU  - Amal Saki Malehi
AU  - Fakher Rahim
TI  - Laboratory findings, signs and symptoms, clinical outcomes of Patients with COVID-19 Infection: an updated systematic review and meta-analysis
AID  - 10.1101/2020.03.25.20043703
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.25.20043703
4099  - http://medrxiv.org/content/early/2020/03/30/2020.03.25.20043703.short
4100  - http://medrxiv.org/content/early/2020/03/30/2020.03.25.20043703.full
AB  - Background and Aim Coronaviruses disease 2019 (COVID-19), for the first time detected in Wuhan, China, rapidly speared around the world and be a Public Health Emergency of International Concern (PHEIC). The aim of the current survey is collecting laboratory findings, analysis them and reporting a specific pattern for help to COVID-19 diagnosis.Methods To collect laboratory characteristics, we searched “PubMed” electronic database with the following keywords: “COVID-19” “2019 novel coronavirus” “laboratory findings” “clinical characteristics”.Results Once the initial searches 493 studies were yielded. After removing duplicates studies 480 studies were remained. The 12 studies obtained from the literature, of which 58.3% (7) of studies were case-control (8–14), and 41.7% (5) remaining studies were designed as cross-sectional (1,15–18)Conclusion The result of the current study showed that in the early stage of COVID-19 infection, maybe there are not significant laboratory findings, but with disease progression, the one or more than signs include increasing AST, ALT, LDH, CK, CRP, ESR, WBC, neutrophil, and decreasing Hemoglobin, lymphocyte count, eosinophil count can be seen. Elevating D-dimer and FDP are associated with ARDS development and can be used as prognostic factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundings are applicable.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in manuscript.